Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Premarket Approval (PMA)
  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 


New Search Back to Search Results
Note: This medical device record is a PMA supplement. A supplement may have changed the device description/function or indication from that approved in the original PMA. Be sure to look at the original PMA record for more information.
 
DeviceTAXUS EXPRESS2 PACLITAXEL CORONARY STENT SYSTEM
Generic NameCoronary drug-eluting stent
ApplicantBoston Scientific Corp
One Scimed Place
Maple Grove, MN 55311-1566
PMA NumberP030025
Supplement NumberS021
Date Received08/02/2005
Decision Date09/24/2008
Withdrawal Date12/06/2018
Product Code NIQ 
Advisory Committee Cardiovascular
Supplement TypeNormal 180 Day Track
Supplement Reason Labeling Change - Indications/instructions/shelf life/tradename
Expedited Review Granted? No
Combination ProductYes
Predetermined Change Control Plan AuthorizedNo
Approval Order Statement  
APPROVAL FOR STENT DIAMETERS WHICH EXPAND THE PRODUCT MATRIX TO INCLUDE 2.25 MM AND 4.0MM TAXUS EXPRESS2 PACLITAXEL-ELUTING CORONARY STENT SYSTEMS. THE DEVICE, ASMODIFIED, WILL BE MARKETED UNDER THE TRADE NAME TAXUS EXPRESS2 PACLITAXEL-ELUTINGCORONARY STENT SYSTEM (MONORAIL, MR AND OVER-THE-WIRE, OTW) AND IS INDICATED FOR THEFOLLOWING: THE TAXUS EXPRESS PACLITAXEL-ELUTING CORONARY STENT SYSTEM IS INDICATED FOR IMPROVINGLUMINAL DIAMETER FOR THE TREATMENT OF DE NOVO LESIONS IN NATIVE CORONARY ARTERIES >2.25 TO<4.0MM IN DIAMETER IN LESIONS < 28MM IN LENGTH.
Post-Approval StudyShow Report Schedule and Study Progress
-
-